Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Nivo + ipi in unresectable stage III/IV melanoma

Michael Postow • 27 May 2020
ASCO 2020
Melanoma Ipilimumab Nivolumab

Michael Postow, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, USA, talks through data from a phase II study (NCT03122522) evaluating the need for more than two doses of nivolumab and ipilimumab combination immunotherapy in patients with unresectable stage III/IV melanoma.This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology),

More from Michael Postow

10:42
What is new in melanoma?
Michael Postow • 8 Oct 2020
3:02
Areas of unmet needs in melanoma
Michael Postow • 6 Oct 2020
3:31
Combination radiotherapy + checkpoint blockade in patients with advanced melanoma
Michael Postow • 7 Oct 2020

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals